GLPBio

Cell Cycle/Checkpoint

Cell Cycle/Checkpoint

Cell Cycle

Cells undergo a complex cycle of growth and division that is referred to as the cell cycle. The cell cycle consists of four phases, G1 (GAP 1), S (synthesis), G2 (GAP 2) and M (mitosis). DNA replication occurs during S phase. When cells stop dividing temporarily or indefinitely, they enter a quiescent state called G0.

Research Areas

Products Related to Cell Cycle/Checkpoint(1553)

  • GC73885 structure
    GC73885PLK1/BRD4-IN-3
    CAS: 2251709-91-6
    Purity: >99.00%

    PLK1/BRD4-IN-3 (Compound 21) is a selective dual inhibitor for bromodomain 4 (BRD4) and polo-like kinase 1 (PLK1).

  • GC73973 structure
    GC73973MY-1442
    CAS: 3050871-87-6
    Purity: >99.00%

    MY-1442 (I-3) is a microtubulin polymerization inhibitor.

  • GC73983 structure
    GC73983MYC degrader 1
    CAS: 2946670-96-6
    Purity: >99.00%

    MYC degrader 1 (compound A80.2HCl) is an orally available MYC degrader with antitumor activity.

  • GC73984 structure
    GC73984MYC degrader 1 TFA
    Purity: >99.00%

    MYC degrader 1 TFA is a MYC degrader that restores pRB1 protein activity and reduces MYC-dependent CDK4/6 resistance.

  • GC74000 structure
    GC74000DBPR728
    CAS: 2702965-64-6
    Purity: >98.00%

    DBPR728 is an acyl prodrug of 6K465 that carries fewer drogen bond donors.

  • GC74022 structure
    GC74022Tubulin/NEDDylation-IN-1
    Purity: >98.00%

    Tubulin/NEDDylation-IN-1 (compound C11) is a dual inhibitor of tubulin (Microtubule/Tubulin)-NEDDylation (IC50 for tubulin=2.40 μM), which has strong anti-proliferative activity.

  • GC74061 structure
    GC74061DBM-C5-VC-PAB-MMAE
    CAS: 1644228-55-6

    DBM-C5-VC-PAB-MMAE (Compound 3a) is a Drug-Linker conjugate for ADC.

  • GC74069 structure
    GC74069NH2-PEG3-VC-PAB-MMAE
    CAS: 2641442-97-7
    Purity: >99.00%

    NH2-PEG3-VC-PAB-MMAE is a drug-linker conjugate for ADC, consisting of a cleavable ADC linker (NH2-PEG3-VC-PAB) and a potent tubulin inhibitor Monometl auristatin E (MMAE).

  • GC74104 structure
    GC74104Lisavanbulin dihydrochloride
    CAS: 1387574-54-0
    Purity: >99.00%

    Lisavanbulin (BAL-101553) didrochloride is the prodrug of the microtubule targeting agent Avanbulin (BAL 27862).

  • GC74126 structure
    GC74126ER-076349
    CAS: 253128-15-3
    Purity: >99.00%

    ER-076349 is an inhibitor of tubulin polymerization, induces G2-M cell cycle arrest, and disrupts mitotic spindles.

  • GC74159 structure
    GC74159MK-0731
    CAS: 845256-65-7
    Purity: >99.00%

    MK-0731 is a selective, non-competitive and allosteric kinesin spindle protein (KSP) inhibitor with an IC50 of 2.2 nM and a pKa of 7.6.

  • GC74279 structure
    GC74279Ganoderic acid T-Q
    CAS: 112430-66-7
    Purity: >99.00%

    Ganoderic acid T-Q (Ganodermic acid T-Q) (compound 1) is a natural product that can be found in ganoderma lucidum.

  • GC74280 structure
    GC74280Dihydrobaicalein
    CAS: 35683-17-1
    Purity: >99.00%

    Didrobaicalein is a PLK1 Inhibitor with an IC50 of 6.3 μM.

  • GC74316 structure
    GC74316ATR kinase substrate peptide
    Purity: >99.00%

    ATR kinase substrate peptide (compound 45) is a potent and selective inhibitor of ATR (Ataxia Telangiectasia and Rad3 related) protein kinase (Ki=6 nM).

  • GC74326 structure
    GC74326MPSD TFA
    Purity: >98.00%

    MPSD TFA (MARCKS-ED TFA) is the TFA salt form of MPSD.

  • GC74519 structure
    GC74519Cantuzumab ravtansine
    CAS: 868747-45-9
    Purity: >98.00%

    Cantuzumab ravtansine (IMGN242; huC242-DM4), an ADC, is a humanized monoclonal antibody, huC242, covalently linked via a disulfide bond to DM4 (DM4 ).

  • GC74533 structure
    GC74533Tusamitamab ravtansine
    CAS: 2254086-60-5
    Purity: >99.00%

    Tusamitamab ravtansine (SAR-408701) is a targeted ADC against tumor cells expressing CEACAM5, composed of a humanized anti-CEACAM5 monoclonal antibody covalently linked to the potent cytotoxic agent, maytansinoid DM4 , via a cleavable linker.

  • GC74600 structure
    GC74600Cofetuzumab pelidotin
    CAS: 1869937-48-3
    Purity: >99.00%

    Cofetuzumab pelidotin (PF-06647020) is a PTK7-targeting ADC comprising a humanized anti-PTK7 mAb joined to an auristatin microtubule inhibitor payload, auristatin-0101, by a cleavable valine-citrulline (vc)-based linker.

  • GC78758 structure
    GC78758Mal-Val-Lys-PAB-MMAE TFA
    Purity: >98.00%

    Mal-Val-Lys-PAB-MMAE TFA is a drug-linker conjugate for ADC.

  • GC78762 structure
    GC78762Trastuzumab-DM4
    Purity: >98.00%

    Trastuzumab -DM4 is an antibody-drug conjugate (ADC) formed by conjugating Trastuzumab with DM4 (sulfo-SPDB-DM4) via a cleavable linker.

  • GC78763 structure
    GC78763ADC Control Human IgG1-sulfo-SPDB-DM4
    Purity: >98.00%

    ADC Control Human IgG1-sulfo-SPDB-DM4 is an antibody-drug conjugate (ADC) and can inhibit tubulin polymerization.

  • GC78764 structure
    GC78764Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE
    CAS: 3103526-19-5
    Purity: >97.50%

    Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC.

  • GC78765 structure
    GC78765LP-6 TFA
    CAS: 1629741-09-8
    Purity: >98.00%

    LP-6 TFA is a Drug-Linker Conjugate for ADC, and can be used for synthesis of ADCs.

  • GC78766 structure
    GC78766N-(Mal)-N-(PEG8-Val-Cit-PAB-MMAE)-N-(PEG8-Val-Cit-PAB-Exatecan)
    Purity: >98.00%

    N-(Mal)-N-(PEG8-Val-Cit-PAB-MMAE)-N-(PEG8-Val-Cit-PAB-Exatecan) is a drug-linker conjugate for ADC (Drug-Linker Conjugate for ADC), consisting of a tubulin polymerization inhibitor MMAE and a DNA topoisomerase I inhibitor Exatecan, and an ADC linker composition.